Filing Summary
Business context and reporting period
Upjohn Inc. filed a Form 8-K on August 6, 2020, under Item 7.01 (Regulation FD Disclosure). The filing concerns the planned separation of Pfizer’s Upjohn Business and its combination with Mylan, which was expected to create the company later known as Viatris. This is a transaction update, not a periodic financial-results filing.
Transaction status and key terms
- Pfizer plans to contribute the Upjohn Business to Upjohn Inc. in a separation transaction.
- Pfizer then plans to distribute Upjohn Inc. common stock pro rata to Pfizer shareholders.
- Immediately afterward, Upjohn Inc. is expected to combine with Mylan.
- Following completion, Pfizer shareholders are expected to own 57% of the fully diluted shares of the combined company; Mylan shareholders are expected to receive one share of the combined company for each Mylan ordinary share, subject to applicable withholding taxes.
- The Form 10 registration statement became effective on June 30, 2020. The final information statement dated August 6, 2020 was filed as Exhibit 99.1, and Pfizer began mailing notices regarding availability of the materials.
- The Pfizer board had not yet established or publicly announced the record date or distribution date as of the filing.
- Closing remained subject to customary conditions, including receipt of regulatory approvals.
Financial metrics and liquidity
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other periodic financial metrics. No financial statements or earnings guidance are reported in the filing.
Outlook, risks, and contingencies
Forward-looking statements address the expected timing and completion of the transaction, potential benefits and synergies, future operating performance, capital allocation, dividend policy, debt ratios, and other targets. Management cautions that actual results may differ materially.
- Key contingencies include regulatory approvals, satisfaction or waiver of closing conditions, and the parties’ ability to complete the separation and combination on the expected timetable.
- Identified risks include COVID-19 impacts, integration difficulties, failure to achieve projected synergies, customer or employee loss, financing and liquidity constraints, manufacturing and supply-chain issues, product demand and pricing uncertainty, competition, intellectual-property and litigation matters, regulatory actions, and changes in tax or other laws.
- The filing states that additional transaction risks are described in the Form S-4, Form 10, Mylan proxy statement, prospectus, and other SEC filings.
Important facts to verify
- Verify the final record date and distribution date established by Pfizer.
- Verify whether all regulatory approvals and other closing conditions were satisfied.
- Review the final information statement and related SEC filings for transaction structure, pro forma financial information, indebtedness, tax matters, and risk factors.
- Confirm the final ownership percentages and share issuance mechanics after closing.
- Determine whether the transaction ultimately closed and the timing of the combined company’s transition to Viatris.